BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 11887034)

  • 1. Selected parameters of fibrinolysis system in patients with dermatitis herpetiformis.
    Wankiewicz A; Iwan-Zietek I; Kotschy M; Gwieździński Z
    Med Sci Monit; 2002 Mar; 8(3):CR189-92. PubMed ID: 11887034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrinolysis system in patients with bronchial asthma.
    Banach-Wawrzeńczyk E; Dziedziczko A; Rość D
    Med Sci Monit; 2000; 6(1):103-7. PubMed ID: 11208294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
    Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
    Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasminogen activators t-PA, u-PA and its inhibitor (PAI) in normal males and females.
    Koh SC; Yuen R; Viegas OA; Chua SE; Ng BL; Sen DK; Ratnam SS
    Thromb Haemost; 1991 Nov; 66(5):581-5. PubMed ID: 1803623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levels of F(1+2) prothrombin fragments and thrombin - antithrombin III (TAT) complexes in patients with dermatitis herpetiformis.
    Wankiewicz A; Iwan-Zietek I; Gwieździński Z; Kotschy M
    Med Sci Monit; 2002 Aug; 8(8):BR324-7. PubMed ID: 12165736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Tissue plasminogen activator (t-PA) in aqueous humor of patients with cataract].
    Kotschy M; Kałuzny J; Kaniasty M; Zekanowska E; Kropińska E
    Klin Oczna; 1996 Mar; 98(3):201-3. PubMed ID: 9019589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depression of tissue-type plasminogen activator and enhancement of urokinase-type plasminogen activator as an expression of local inflammation.
    Brommer EJ; Dooijewaard G; Dijkmans BA; Breedveld FC
    Thromb Haemost; 1992 Aug; 68(2):180-4. PubMed ID: 1412164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-traumatic plasminogenesis in intraarticular exudate in the knee joint.
    Rość D; Powierza W; Zastawna E; Drewniak W; Michalski A; Kotschy M
    Med Sci Monit; 2002 May; 8(5):CR371-8. PubMed ID: 12011780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Activation of fibrynolysis in children with chronic B or C hepatitis].
    Michalska K; Szaflarska-Popławska A; Dymek G; Kotschy M
    Pol Merkur Lekarski; 2004 Oct; 17(100):316-20. PubMed ID: 15690691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrinolysis and coagulation in patients with infectious disease and sepsis.
    Philippé J; Offner F; Declerck PJ; Leroux-Roels G; Vogelaers D; Baele G; Collen D
    Thromb Haemost; 1991 Mar; 65(3):291-5. PubMed ID: 1904655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.
    Ferguson JW; Helmy A; Ludlam C; Webb DJ; Hayes PC; Newby DC
    Thromb Res; 2008; 121(5):675-80. PubMed ID: 17870147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Levels of tissue-type plasminogen activator (T-PA), its inhibitor (PAI-1) and fibrinogen in the blood of patients with type 1 and 2 diabetes mellitus].
    Kvasnicka J; Skrha J; Perusicová J; Maslowská H; Pochopová L
    Cas Lek Cesk; 1996 Mar; 135(6):174-7. PubMed ID: 8681360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Plasminogen activators (t-PA and u-PA) and other fibrinolysis parameters in patients with atherosclerosis obliterans and diabetic macroangiopathy].
    Zalewska-Rydzkowska D; Rość D; Ponikowska I; Michalski A; Graczykowska-Koczorowska A; Rydzkowski M
    Pol Merkur Lekarski; 2001 Nov; 11(65):414-7. PubMed ID: 11852811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levels of fibrinolytic activators and inhibitors in plasma after severe trauma.
    Sørensen JV
    Blood Coagul Fibrinolysis; 1994 Feb; 5(1):43-9. PubMed ID: 7514044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hemostatic disturbances in chronic myeloid leukemia].
    Rość D; Kremplewska-Nalezyta E; Gadomska G; Bielis L
    Wiad Lek; 2007; 60(3-4):138-42. PubMed ID: 17726865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of long-term erythropoietin therapy on fibrinolytic system in haemodialyzed patients.
    Pawlak K; Pawlak D; Mysliwiec M
    Thromb Res; 2008; 121(6):787-91. PubMed ID: 17869326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity.
    Agren A; Wiman B; Schulman S
    Blood Coagul Fibrinolysis; 2007 Oct; 18(7):657-60. PubMed ID: 17890953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasminogen activators and plasminogen activator inhibitors in liver deficiencies caused by chronic alcoholism or infectious hepatitis.
    Tran-Thang C; Fasel-Felley J; Pralong G; Hofstetter JR; Bachmann F; Kruithof EK
    Thromb Haemost; 1989 Sep; 62(2):651-3. PubMed ID: 2510345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasminogen activator inhibitor type-1 determines plasmin formation in patients with ischaemic heart disease.
    Pedersen OD; Gram J; Jespersen J
    Thromb Haemost; 1995 May; 73(5):835-40. PubMed ID: 7482412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of chronic mercury poisoning on blood coagulation and fibrinolysis systems].
    Song YG
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2005 Dec; 23(6):405-7. PubMed ID: 16405768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.